Results 11 to 20 of about 16,411 (192)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. [PDF]

Br J Clin Pharmacol
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Op 't Hoog CJP, Mehra N, van Kleef A, Somford DM, van Oort IM, Imholz ALT, Hamberg P, van Erp NP, Boerrigter E.   +8 more
europepmc   +2 more sources

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction Edoxaban is the only anti‐Xa inhibitor metabolized in pharmacologically active moiety that could interfere with chromogenic anti‐Xa assays, especially in case of drug‐drug interactions or physiological disorders.
Romain Siriez, Halil Yildiz, Céline Bouvy, Hélène Haguet, Vincent Maloteau, Michaël Hardy, François Mullier, Jean‐Michel Dogné, Philippe Hainaut, Jonathan Douxfils   +9 more
doaj   +1 more source

Edoxaban [PDF]

Reactions Weekly, 2021
Kirsten Mitchell, Andrea Llano
  +8 more sources

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Neurological Research and Practice, 2021
Background Direct oral anticoagulants (DOAC) including edoxaban are increasingly used for stroke prevention in atrial fibrillation. Despite treatment, annual stroke rate in these patients remains 1–2%.
Florian Härtig, Ingvild Birschmann, Andreas Peter, Sebastian Hörber, Matthias Ebner, Matthias Sonnleitner, Charlotte Spencer, Paula Bombach, Maria-Ioanna Stefanou, Johannes Tünnerhoff, Annerose Mengel, Joachim Kuhn, Ulf Ziemann, Sven Poli   +13 more
doaj   +1 more source

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation

Cardiology and Therapy, 2023
Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for the prevention of thromboembolism in patients with atrial fibrillation (AF).
Giuseppe Patti, Rosa Wang, Xiaocong Li Marston, Yu-Chen Yeh, Lisa Zimmermann, Xin Ye, Xin Gao, Bernd Brüggenjürgen   +7 more
doaj   +1 more source

Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study

Brain Sciences, 2023
Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings.
Irene Scala, Simone Bellavia, Pier Andrea Rizzo, Jacopo Di Giovanni, Mauro Monforte, Roberta Morosetti, Giacomo Della Marca, Fabio Pilato, Aldobrando Broccolini, Paolo Profice, Giovanni Frisullo   +10 more
doaj   +1 more source

Safety and Efficacy of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebrovascular Ischemic Outcomes in Non-Valvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. [PDF]

Clin Cardiol
Direct Oral Anticoagulants (DOACs) were associated With lower rates of cerebrovascular ischemic events and major bleeding compared With Vitamin K antagonists in non‐valvular atrial fibrillation, With similar mortality. These findings support DOACs as the preferred anticoagulant strategy for stroke prevention in contemporary clinical practice.
Nasir A, Anwar N, Kamran AB, Muhammad A, Haider A, Mubashar M, Tariq F, Helou M, Shami B.   +8 more
europepmc   +2 more sources

The year in cardiology: arrhythmias and pacing. [PDF]

, 2020
During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H, Camm, AJ, Lip, GYH, Schilling, R, Steffel, J   +4 more
core   +4 more sources

Study of weight variation and dissolution of Edoxaban split tablets in pharmacy practice [PDF]

Pharmaceutical Sciences Asia, 2022
Edoxaban is available in 60 mg, 30 mg, and 15 mg unscored film-coated tablets. Tablet splitting may be an option to reduce medication costs and reduce the country’s budget.
Mantiwee Nimworapan, Sinwisuth Sutheechai, Wanwarang Wongcharoen, Arintaya Phrommintikul, Suntara Eakanunkul   +4 more
doaj   +1 more source